Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 107
Appendix B
Monday, July 16, 2001
Meeting Agenda
IMMUNIZATION SAFETY REVIEW COMMITTEE
Thimerosal-Containing Vaccines and
Neurodevelopmental Outcomes
Public Meeting
The Charles Hotel
Conant Wadsworth B Conference Room
One Bennett Street
Cambridge, MA
PUBLIC SESSION
8:00-8:10 a.m. Welcome and Introductions
Marie McCormick, M.D., Sc.D.
Chair, Immunization Safety Review Committee
8:10-8:30 a.m. Risk Assessment of Thimerosal in Childhood Vaccines
Leslie K. Ball, M.D.
Division of Vaccines and Related Product Applications
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research
Food and Drug Administration
8:30-9:00 a.m. History of Thimerosal Concern and Comparative Policy
Actions
Gary L. Freed, M.D.
The Percy and Mary Murphy Professor of Pediatrics and
Child Health Delivery
Director, Division of General Pediatrics
Professor of Health Management and Policy
University of Michigan
107
OCR for page 108
108
IMMUNIZA TION SAFETY RE VIE W
Margie Andreae, M.D.
Associate Director for Clinical Services
Division of General Pediatrics
University of Michigan
9:00-9:35 a.m. Biologic Plausibility and Planned Research
Jane M. El-Dahr, M.D.
Head, Section of Pediatric Allergy, Immunology, Rheumatology
Tulane University Health Sciences Center
David S. Baskin, M.D.
Professor of Neurosurgery
Baylor College of Medicine
9:35-10:00 a.m. The Role of Heavy Metals in Autism
Jeffrey Bradstreet, M.D.
Director of Research
The International Autism Research Center
10:15-10:45 a.m. Pharmacokinetic Modeling of Hair Mercury Levels from
Thimerosal
David Brown, Sc.D.
Toxicologist and Independent Consultant
Connecticut
10:45 -11:30 a.m. Vaccine Safety Datalink (VSD) Screening Study and Fol-
low-Up Analysis with Harvard Pilgrim Data
Thomas Verstraeten, M.D., M.Sc.
EIS Officer, National Immunization Program
Centers for Disease Control and Prevention
11:30-12:00noonProtocol for National Immunization Program Study on
Thimerosal
Paul Stehr-Green, Dr.P.H., M.P.H.
Associate Professor of Epidemiology
University of Washington School of Community Medicine and
Public Health
William Thompson, Ph.D. For Q&A period only
Epidemiologist, National Immunization Program
Centers for Disease Control and Prevention
OCR for page 109
APPENDIXB: MEETING AGENDA
1:00 -1 :30 p.m. Seychelles Islands Study
Gary Myers, M.D.
Professor of Neurology and Pediatrics
University of Rochester School of Medicine and Dentistry
1 :30-2:00 p.m.
Faroe Islands Study
Philippe Grandjean, M.D., D.M.Sc.
Institute of Community Health
Odense University, Denmark
2:00-2:30 p.m. In Vitro Studies of Thimerosal Toxicity
Boyd E. Haley, Ph.D.
Chairman and Professor, Department of Chemistry
University of Kentucky
2:30-3:00 p.m. Comparative Toxicology of Ethyl and Methyl Mercury
George Lucier, Ph.D.
Former Director, Environmental Toxicology Program
National Institute for Environmental Health Sciences
3:15-3:30 p.m. Rising Incidence of Autism: Association with Thimerosal
Mark F. Blaxill, M.B.A.
Autism Society of America, Massachusetts Chapter
3:30-3:45 p.m. NIH Studies on Thimerosal
Polly Sager, Ph.D.
National Institute of Allergy and Infectious Diseases
National Institutes of Health
3 :45-4: 10 p.m. Wrap-Up Commentary on Thimerosal Risk
From the Perspective of a Developmental Toxicologist
George Lambert, M.D.
Environmental and Occupational Health Sciences Institute
Robert Wood Johnson Medical School
4:10-4:35 p.m. Wrap-up Commentary on Thimerosal Risk
From the Perspective of a Pediatric Vaccinologist
Neal Halsey, M.D.
Professor and Director
Division of Disease Control
Department of International Health
The Johns Hopkins University
4:35-5:00 p.m. Public comment period
109
OCR for page 110
Representative terms from entire chapter:
immunization program
